मिसिल स.- 8(153)/2026/डी.पी/एनपीपीए-डीवी-II
F. No. 8(153)/2026/DP/NPPA-Div. II

कार्यवाही स. : 285/153/2026/F
Proceeding No: 285/153/2026/F

Minutes of the 285th (overall) and 153rd meeting of the Authority under DPCO, 2013 held on 29.10.2026 at 04:30 PM.

The 285th meeting of the Authority (overall), which is the 153rd meeting under the DPCO, 2013 was held on 29.10.2026 at 04:30 PM under the Chairmanship of Shri Manoj Joshi, Secretary, D/o Pharmaceuticals & Chairman, NPPA. The following Authority members were present during the meeting:

(i) Ms. Sai Ahlladini Panda, Member Secretary, NPPA
(ii) Shri Anand Kumar Pal, Chief Adviser (Cost), O/o Chief Adviser Cost, Department of Expenditure

Shri Arvind Kukrety, Deputy Drugs Controller, CDSCO, Ministry of Health & Family Welfare.

The following officers of NPPA attended the meeting and assisted the Authority in its deliberations:

(i) Shri Rajiv Wadhawan, Adviser (Cost)
(ii) Ms. Priyanka Sachdeva, Joint Director (Pricing)
(iii) Shri Bhiva Ram Yadav, Assistant Director (Pricing)
(iv) Shri Mayur Panwar, Assistant Director (Pricing)

At the outset, Member Secretary, welcomed all the participants.

1. Agenda item no. 1 - Confirmation of minutes of: (a) 150th Meeting held on 25.08.2026; (b) 151st Meeting held on 08.10.2026; and (c) 152nd Meeting held on 16.10.2026 & 17.10.2026.

1.1 The Authority confirmed the minutes of the meetings without any change.

2. Agenda item no. 2 – Action Taken Report (ATR) on decisions taken by NPPA in its (a) 150th Meeting held on 25.08.2026; (b) 151st Meeting held on 08.10.2026; and (c) 152nd Meeting held on 16.10.2026 & 17.10.2026.

2.1 Noted.

3. Agenda item no. 3 – Status of new drug applications.

3.1 Noted.

4. Agenda item no. 4 – New Drug application for price fixation under Paragraph 5 and 15 of DPCO, 2013.

4.1 The Authority deliberated on 35 (Thirty-Five) cases of retail price fixation of new drugs as presented in Agenda no. 4(1) to 4(35) falling under the purview of paragraph 2(1)(u) of DPCO, 2013. The Authority approved the retail prices of 35 (Thirty-Five) new drugs under paragraph 5 and 15 of DPCO, 2013 as given in **Table 1 below:**

Table No. 1: Retail price fixation of new drugs

Sl. No.	Agenda Item No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (₹)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	4(1)	Alginate Raft-forming Oral Suspension B.P.	Each 5 ml contains: Sodium Alginate IP 250 mg, Sodium Bicarbonate IP 133.5 mg, Calcium Carbonate IP 80mg	1 ML	M/s ESPI Industries & Chemicals Pvt Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd.	0.97
2	4(2)	Amoxycillin and Potassium Clavulanate for Oral Suspension	Each Combipack Contains: (A) 1 Bottle of Amoxycillin and Potassium Clavulanate for Oral Suspension IP Each 5 ml of Constituted Suspension Contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 400 mg Potassium Clavulanate Diluted IP Eq. to Clavulanic Acid 57 mg (B) 1 Vial of Sterile Water for Injections IP Each Vial Contains: Sterile Water for Injections IP 30 ml	1 ML	M/s Malik Lifesciences Pvt. Ltd./ M/s Apex Laboratories Pvt. Ltd.	5.10
3	4(3)	Benfotiamine, Methylcobalamin, Alpha Lipoic Acid, Folic Acid, Chromium Picolinate, Myo-Inositol, Pyridoxine Hydrochloride Tablets	Each Film Coated Tablet Contains: Benfotiamine 200 mg Methylcobalamin IP 1500 mcg Alpha Lipoic Acid IP 200 mg Folic Acid IP 1.5 mg Chromium Picolinate IP 200 mcg Myo-Inositol IP 100 mg Pyridoxine Hydrochloride IP 3 mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Cipla Ltd.	24.01
4	4(4)	Ceftriaxone & Tazobactam Injection	Each Vial Contains: Sterile Ceftriaxone Sodium IP eq. to Ceftriaxone anhydrous 500 mg Sterile Tazobactam Sodium IP eq. to Tazobactam 62.5 mg	1 Vial	M/s Maya Biotech Pvt. Ltd./ M/s Vivaldis Health and Foods Pvt. Ltd.	125.07 **(Note-1)**
5	4(5)	Ciprofloxacin and Dexamethasone Eye Drops	Composition: Ciprofloxacin Hydrochloride IP eq. to Ciprofloxacin 0.3% w/v Dexamethasone IP 0.1% w/v Benzalkonium Chloride Solution IP 0.02% v/v (As Preservative)	1 ML	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Wellgen Medicare LLP	2.71
6	4(6)	Doxylamine Succinate & Pyridoxine Hydrochloride Extended-Release Tablets	Each Film Coated Extended-Release Tablet Contains: Doxylamine Succinate USP 20 mg Pyridoxine Hydrochloride IP 20 mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Mankind Pharma Ltd.	13.14

7	4(7)	Gemcitabine Injection 1.4g/36.84 ml	Each ml contains: Gemcitabine Hydrochloride IP Eq. to Gemcitabine 38 mg	1 Vial	M/s Adley Formulations Pvt. Ltd.	5623.07
8	4(8)	Gentamicin Sulphate, Dexamethasone Sodium Phosphate Eye/Ear Drops	Gentamicin Sulphate IP Eq. to Gentamicin base 0.3% w/v Dexamethasone Sodium Phosphate IP Eq. to Dexamethasone Phosphate 0.1% w/v Sodium Methylparaben IP 0.05% w/v (as Preservative) Sodium Propylparaben IP 0.01% w/v (as Preservative)	1 ML	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Wellgen Medicare LLP	1.75
9	4(9)	Ibuprofen & Paracetamol suspension	Each 5 ml contains: Ibuprofen IP 100 mg Paracetamol IP 162.5 mg	1 ML	M/s Innova Captab Ltd./ M/s Torrent Pharmaceuticals Ltd	0.60
10	4(10)	Metformin (Extended-Release) and Sitagliptin Tablets	Each Film coated tablet contains: Metformin Hydrochloride IP 500mg (As Extended Release) Sitagliptin Phosphate Monohydrate IP Eqv. to Sitagliptin 100mg	1 Tablet	M/s Synokem Pharmaceuticals Ltd./ M/s FDC Ltd.	13.92
11	4(11)	Methotrexate Oral Solution	Each ml contains: Methotrexate IP 2 mg	1 ML	M/s Beta Drugs Ltd./ M/s Ipca Laboratories Ltd.	12.70
12	4(12)	Methylprednisolone Tablets	Each uncoated tablet contains: Methylprednisolone IP 4 mg	1 Tablet	M/s Foregen Healthcare Ltd./ M/s Zorvia Healthcare Ltd.	5.30
13	4(13)	Methylprednisolone Tablets	Each uncoated tablet contains: Methylprednisolone IP 16 mg	1 Tablet	M/s Foregen Healthcare Limited/ M/s Zorvia Healthcare Ltd.	10.28
14	4(14)	Moxifloxacin Eye Drops IP	Composition: Moxifloxacin Hydrochloride IP eq. to Moxifloxacin 0.5% w/v Benzalkonium Chloride Solution IP 0.02% w/v (As Preservative)	1 ML	M/s Skymap Pharmaceuticals Pvt. Ltd/ M/s Wellgen Medicare LLP	35.37
15	4(15)	Moxifloxacin Hydrochloride & Dexamethasone Phosphate Eye Drops	Each ml contains: Moxifloxacin Hydrochloride IP eq. to Moxifloxacin 0.5% w/v Dexamethasone Sodium Phosphate IP Eq. to Dexamethasone Phosphate 0.1% w/v Benzalkonium Chloride Solution IP 0.01% v/v (As Preservative)	1 ML	M/s Skymap Pharmaceuticals Pvt. Ltd/ M/s Wellgen Medicare LLP	20.40
16	4(16)	Multivitamin and Multi Mineral drops	Each ml Contains: Cholecalciferol (as stabilized) IP 200 IU Pyridoxine HCL IP 0.5 mg Niacinamide IP 5 mg Cyanocobalamin IP 1 mcg Sodium Selenite Pentahydrate BP eq. to	1 ML	M/s Ordain Healthcare Global Pvt. Ltd/ M/s Mapra Laboratories Pvt. Ltd.	3.20

			elemental Selenium 10 mcg Zinc Sulphate Monohydrate IP eq. to elemental Zinc 2 mg Manganese Sulphate Monohydrate BP eq. to elemental Manganese 3 mcg Sodium Molybdate dihydrate BP eq. to elemental Molybdenum 1 mcg L-Lysine hydrochloride IP 30 mg Potassium Iodide IP eq. to elemental Iodine 20 mcg Biotin IP 5 mcg Chromium Picolinate IP eq. to elemental Chromium 1 mcg Myo-inositol IP 10 mg Beta carotene Dispersion 2.5 % 18 mg			
17	4(17)	myo-Inositol and Metformin Hydrochloride (SR) Tablets	Each Film Coated Bilayered Tablet Contains: myo-Inositol IP 600 mg Metformin Hydrochloride IP 500 mg (As sustained release)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Zorvia Healthcare Ltd.	24.45
18	4(18)	Paracetamol and Mefenamic Acid Suspension	Each 5 ml contains: Paracetamol IP 250 mg Mefenamic Acid IP 100 mg	1 ML	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Profic Organic Ltd.	0.95
19	4(19)	Paracetamol and Caffeine Tablets	Each uncoated tablet contains: Paracetamol IP 650 mg Caffeine Anhydrous IP 50 mg	1 Tablet	M/s Alkem Health Science (A Unit of Alkem Laboratories Ltd) Unit-2/ M/s Alkem Laboratories Ltd.	3.84
20	4(20)	Rosuvastatin, Aspirin and Clopidogrel Capsules	Each Hard Gelatin Capsule Contains: Rosuvastatin Calcium IP Eq. to Rosuvastatin 20 mg (As film coated tablet) Aspirin IP 75 mg (As Gastro - resistant Tablet) Clopidogrel Bisulphate IP Eq. to Clopidogrel 75 mg (as film coated tablet)	1 Capsule	M/s Akums Drugs & Pharmaceuticals Ltd/ M/s Sun Pharmaceutical Industries Ltd	25.21
21	4(21)	Rosuvastatin, Aspirin and Clopidogrel Capsules	Each Hard Gelatin Capsule Contains: Rosuvastatin Calcium IP Eq. to Rosuvastatin 10 mg (As film coated tablet) Aspirin IP 75 mg (As Gastro - resistant Tablet) Clopidogrel Bisulphate IP Eq. to Clopidogrel 75 mg (as film coated tablet)	1 Capsule	M/s Akums Drugs & Pharmaceuticals Ltd/ M/s Sun Pharmaceutical Industries Ltd	16.56
22	4(22)	Tranexamic Acid and Mefenamic Acid Tablets	Each film coated tablet contains: Tranexamic Acid IP 500 mg Mefenamic Acid IP 250 mg	1 Tablet	M/s Synokem Pharmaceuticals Ltd./ M/s Ajanta Pharma Ltd.	35.81
23	4(23)	Vitamin D3 (Cholecalciferol) Drops	Each ml contains: Vitamin D3 IP 800 IU (Cholecalciferol)	1 ML	M/s Synokem Lifesciences Pvt. Ltd./ M/s FDC Ltd.	6.36

24	4(24)	Paracetamol Injection 1000 MG/4 ML	Each ml contains: Paracetamol IP 250 mg	1 Vial	M/s Troikaa Pharmaceuticals Ltd.	341.26
25	4(25)	Ondansetron Orally Disintegrating Strips	Each orally disintegrating strip contains: Ondansetron IP 2 mg	1 Strip	M/s Zim Laboratories Ltd / M/s Sun Pharma Laboratories Ltd	15.90
26	4(26)	Ondansetron Orally Disintegrating Strips	Each orally disintegrating strip contains: Ondansetron IP 4 mg	1 Strip	M/s Zim Laboratories Ltd / M/s Sun Pharma Laboratories Ltd	17.25
27	4(27)	Diclofenac Diethylamine, Methyl Salicylate and Menthol Gel	Composition: Diclofenac Diethylamine IP 2.32 % w/w Eq. To Diclofenac Sodium 2% w/w Methyl Salicylate IP 10% w/w Menthol IP 5% w/w	1 Gram	M/s Marine Life Sciences/ M/s Aristo Laboratories Pvt. Ltd.	4.09
28	4(28)	Diclofenac Sodium & Paracetamol Tablets	Each uncoated tablet contains: Diclofenac sodium IP 50 mg Paracetamol IP 325 mg	1 Tablet	M/s Shiva Biogenetic Pharmaceuticals Pvt Ltd./ M/s Aristo Laboratories Pvt. Ltd.	5.92
29	4(29)	Combikit of Clarithromycin, Vonoprazan and Amoxicillin Tablets	Each strip contains: (A) Clarithromycin Tablets IP (2 Tablets) Each Film Coated Tablet Contains: Clarithromycin IP 500 mg (B) Vonoprazan Tablets (2 Tablets) Each Film Coated Tablet Contains: Vonoprazan Fumarate Eq.to Vonoprazan 20 mg (C) Amoxicillin Tablets USP (2 Tablets) Each Film Coated Tablet Contains: Amoxycyllin Trihydrate IP Eq. to Amoxycillin 1000 mg	1 Strip	M/s Malik Lifesciences Pvt. Ltd./ M/s Mankind Pharma Limited	118.52
30	4(30)	Combikit of Vonoprazan and Amoxicillin Tablets	Each strip contains: (A) Vonoprazan Tablets (2 Tablets) Each Film Coated Tablet Contains: Vonoprazan Fumarate Eq. to Vonoprazan 20 mg (B) Amoxicillin Tablets USP (3 Tablets) Each Film Coated Tablet Contains: Amoxycyllin Trihydrate IP Eq. to Amoxycillin 1000 mg	1 Strip	M/s Malik Lifesciences Pvt. Ltd./ M/s Dr. Reddy's Laboratories Limited	50.53
31	4(31)	Combikit of Vonoprazan tablet + Clarithromycin tablet + Amoxicillin Capsules	Each combipack contains: A. Vonoprazan Tablets (2 Tablets) Each film coated tablet contains: Vonoprazan Fumarate eq. to Vonoprazan 20mg B. Clarithromycin tablets (2 Tablets) Each film coated tablet	1 Combipack	M/s Theon Pharmaceuticals Limited/ M/s Zydus Healthcare Limited	122.34

			contains: Clarithromycin IP 500mg C. Amoxycillin Capsules (4 Capsules) Each hard gelatin capsule contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 500mg			
32	4(32)	Bisoprolol Fumarate + Telmisartan + Cilnidipine Tablets	Each film coated bilayered tablet contains: Bisoprolol Fumarate IP 2.5 mg Telmisartan IP 40 mg Cilnidipine IP 10 mg	1 Tablet	M/s Windlas Biotech Limited/ M/s Eris Lifesciences Limited	19.11
33	4(33)	Bisoprolol Fumarate + Telmisartan + Cilnidipine Tablets	Each film coated bilayered tablet contains: Bisoprolol Fumarate IP 5 mg Telmisartan IP 40 mg Cilnidipine IP 10 mg	1 Tablet	M/s Windlas Biotech Limited/ M/s Eris Lifesciences Limited	20.87
34	4(34)	Carbimazole Tablets	Each uncoated tablet contains: Carbimazole IP 2.5 mg	1 Tablet	M/s Abbott Healthcare Pvt. Ltd.	1.34
Without prior price approval case						
35	4(35)	Cholecalciferol Tablets	Each uncoated chewable tablet contains: Cholecalciferol IP 7000 IU	1 Tablet	M/s Windlas Biotech Limited/ M/s Eris Lifesciences Limited	8.93 **(Note-2)**

Note-1: *One of the members of the Authority opined that for this agenda item, claimed price should be notified as the retail price being lower of 'worked out price' and the 'claimed price'. In this regard, it was clarified that the Authority in its 148th meeting, pursuant to Drugs (Prices Control) Amendment Order, 2026 which came into force from 01.07.2026 had decided that, henceforth, the 'worked out price' shall be notified as the 'retail price'. Accordingly, the applicant, as well as any other existing manufacturer covered under the said provisions, shall launch the new drug formulation at a price not exceeding the notified retail price. The applicant, however, is at liberty to launch the new drug formulation at 'claimed price' in case the 'claimed price' is lower than the notified 'retail price'.*

Note-2: *The company had already launched the formulation without obtaining prior price approval from NPPA; therefore, the said retail price is applicable only to the individual manufacturer/marketer.*

5. Agenda item no. 5: Minutes of 80th meeting of the Multidisciplinary Committee of Experts held on 24.09.2026.

5.1 Noted.

6. Agenda item no. 6: Application by M/s. Biodeal Pharmaceuticals Limited for exemption from the provisions of Drug Price Control Order 2013 under Para 32 (iii) for the formulation "Midazolam nasal spray 1.25 mg"

6.1 The Authority noted that the M/s. Biodeal Pharmaceuticals Limited submitted an application seeking exemption under Para 32(iii) of DPCO, 2013 for the formulation "Midazolam Nasal Spray 1.25 mg" on the ground that the product had been developed through indigenous Research & Development (R&D) as a new drug delivery system. The company had submitted the new drug permission granted by CDSCO on 05.05.2025, the State Licensing

Authority's permission and the certificate of recognition of its in-house R&D facility by the DSIR.

6.2 The Authority further noted that the matter was examined by the Multidisciplinary Committee of Experts (MDC) in its various meetings, wherein further clarifications and documentary evidence were sought from the company regarding the product's delivery system and indigenous development. Inputs from CDSCO and the Standing National Committee on Medicines (SNCM) were also sought regarding the first approval of Midazolam Nasal Spray and its inclusion in NLEM, 2022. CDSCO confirmed that the first New Drug Permission for Midazolam Nasal Spray 1.25% w/v was granted to M/s. Biodeal Pharmaceuticals Limited on 05.05.2025 and that the formulation had not been approved by CDSCO earlier. The company subsequently furnished detailed documentary evidence of its indigenous R&D programme, including pharmaceutical development data, scientific justification for the drug delivery system, container-closure system studies, compatibility and microbiological data, device robustness, spray profiling and data relating to drug content per actuation.

6.3 The Authority further noted that the matter was considered by the MDC in its 80th meeting held on 24.09.2026 wherein the Committee observed that the applicant's claim of indigenous development was supported by the DSIR-recognised in-house R&D facility and the detailed pharmaceutical development documentation. Taking into consideration the regulatory confirmation provided by CDSCO regarding the first approval of Midazolam Nasal Spray and the supporting documents submitted by the company, the MDC noted that the formulation met the regulatory basis for consideration under Para 32(iii) of DPCO, 2013. Accordingly, the MDC recommended grant of exemption under Para 32(iii) of DPCO, 2013 to M/s. Biodeal Pharmaceuticals Limited for the formulation "Midazolam Nasal Spray 1.25 mg" for a period of five years from the date of its market approval in India.

6.4 During discussions, one of the members pointed out that *"applicant has submitted that there is no comparator product in the market having same label claim i.e. 4 metered dose"*. However, there is a product 'Midacip' available in the market with same label claim and provided a photocopy of the packshot. Upon analysis, it was observed that the manufacturer of the product is M/s Biodeal Pharmaceuticals Limited. The Authority noted that the matter had already been considered by the MDC in its various meetings and that CDSCO had specifically confirmed that New Drug Permission for Midazolam Nasal Spray 1.25% w/v was first granted to M/s Biodeal Pharmaceuticals Limited on 05.05.2025. The same was confirmed by representative of DCGI during the meeting.

6.5 The Authority noted the observation of the member concerned and deliberated upon the matter in detail and accepted the recommendation of the MDC to grant exemption to M/s. Biodeal Pharmaceuticals Limited for the formulation "Midazolam Nasal Spray 1.25 mg" under Para 32(iii) of DPCO, 2013 for a period of five years w.e.f. 05.05.2025, being the date of grant of market approval by CDSCO.

7. Agenda item no. 7: Status of implementation of Review cases

7.1 Noted.

8. Agenda item no. 8: Revision of ceiling price of "Oxaliplatin Injection 5 mg/ml in 10 ml vial" based on review order

8. 1 The Authority noted that the Department of Pharmaceuticals (DoP) has issued review order No. 31015/39/2023-Pricing(E-23351) dated 30.03.2026 in respect of the Scheduled

formulation, 'Oxaliplatin Injection 5 mg/ml in 10 ml vial', wherein the matter was referred back to NPPA for recalculation of the ceiling price.

8.2 The Authority noted that M/s Dr. Reddy's Laboratories Ltd. had filed a review application against NPPA's notification S.O. No. 194(E) dated 11.01.2023, wherein it was contended that its brand, namely "Dacotin RTU 50 mg/10 ml vial", accounting for nearly 13% of the total market share, had not been considered while calculating the ceiling price of the subject formulation.

8.3 The Authority further noted that initially, the brand "Dacotin RTU" was not considered in the ceiling price calculation as the relevant Form-II/Form-V data had not been filed and the brand was not separately reflected in the Pharmarack database. The Authority noted that, pursuant to the review order, the matter was re-examined by NPPA by incorporating five additional SKUs verified by Pharmarack, including the brand "Dacotin RTU" of M/s Dr. Reddy's Laboratories Ltd. and the SKU "OXITOZ 50 MG INJECTION 25 ML", for which the correct pack size was confirmed as 50 mg/10 ml. The revised ceiling price was calculated using the PTR data for July 2022, consistent with the methodology adopted for the original fixation. The Authority further noted that the revised draft worksheet was uploaded on NPPA's website on 09.09.2026 and no representation had been received against the same.

8.4 The Authority noted the details of the prevailing ceiling price and the revised ceiling price worked out based on the Review Order, as shown below:

Particulars	**Ceiling price notified (₹/vial)**	**Revised ceiling price based on Review Order (₹/vial)**
Price fixed in January 2023	1,992.32	1,990.80
WPI adjustment w.e.f. 01.04.2023	241.51	241.32
Ceiling price w.e.f. 01.04.2023	2,233.83	2,232.12
Ceiling price w.e.f. 01.04.2024	2,233.95	2,232.24
Ceiling price w.e.f. 01.04.2025	2,272.83	2,271.09
Ceiling price w.e.f. 01.04.2026	2,287.59	2,285.84

8.5 Accordingly, the Authority approved the revised ceiling price of 'Oxaliplatin Injection 5 mg/ml in 10 ml vial' at ₹2,285.84 per 10 ml vial, inclusive of WPI revision applicable from 01.04.2026.

9. Agenda item no. 9: Extension of per gram retail price for Diclofenac 2% Gel to M/s Sun Pharmaceutical Industries Limited

9.1 The Authority noted that M/s Sun Pharmaceutical Industries Limited vide its letter dated 15.10.2026 has requested for notification of per gram retail price of Diclofenac 2% Gel which was earlier notified on a pack-size basis vide S.O. 5638(E) dated 02.11.2018 to enable the company to launch the formulation in different pack sizes. The Authority further noted that the existing retail prices correspond to an effective price of ₹6.25 per gram for the notified pack sizes of 10 g, 15 g, 20 g and 30 g.

9.2 The Authority deliberated on the matter and agreed to the request of the company for notification of per gram retail price of 'Diclofenac + Methyl + Menthol GEL (Volini Maxx Gel), Contains: Diclofenac Diethylamine BP 2.32% w/w (eq. to Diclofenac Sodium 2% w/w), Methyl Salcylate IP 10% w/w & Menthol IP 5% w/w', subject to compliance with the applicable provisions of DPCO, 2013 by the company.

The meeting ended with a vote of thanks to the Chair and all the participants in the meeting.

SAI AHLLADINI PANDA

Digitally signed by SAI AHLLADINI PANDA
Date: 2026.11.02 18:29:55 +05'30'

(Sai Ahlladini Panda)
Member Secretary